Shell donates THB 13 million to Ramathibodi Hospital for COVID-19 support
Aug 04, 2021
Bangkok - The Shell Company of Thailand Limited donated 13 million baht to the Faculty of Medicine Ramathibodi Hospital, Mahidol University to support its efforts to address the continuing impacts of the COVID-19 situation in the country.
The Shell Company of Thailand Limited led by Mr. Panun Prachuabmoh, (left), Country Chairman, presents the cheque donation to Ramathibodi Hospital, represented by Professor Piyamitr Sritara, (right), M.D., Dean of Faculty of Medicine Ramathibodi Hospital, Mahidol University. The donation went to support the conversion of patient wards into negative pressure rooms for treating critical COVID-19 patients.
The financial assistance is used to build negative pressure rooms to treat critical COVID-19 patients. The rooms, which can accommodate a total of 34 hospital beds, help increase the hospital’s capacity to accept critical patients while enhancing the safety of medical frontliners.
With the current bed capacity limitation due to increasing number of COVID-19 cases, Ramathibodi Hospital has been converting its conventional patient rooms into Negative Pressure Room with Airborne Infection Isolation systems, which can prevent contagious viruses from spreading and infecting medical staff who are treating the critical patients closely. Therefore, the rooms are especially crucial for patients with respiratory diseases, especially COVID-19.
Mr. Panun Prachuabmoh, Country Chairman, the Shell Company of Thailand Limited, said “Shell is partnering with the Ramathibodi Hospital in providing immediate support to its physicians and healthcare staff, and in turn enable them to save more lives amid the third wave of infections of COVID-19 in the country. Together with the Ramathibodi Hospital, we aim to help the Thai society during these challenging times.”
Professor Piyamitr Sritara, M.D., Dean of Faculty of Medicine Ramathibodi Hospital, Mahidol University said: “Ramathibodi Hospital has partnered with domestic and international sectors to study and understand the emerging disease, and to prepare medical staff and equipment for challenges brought upon by the COVID-19 outbreak. With Shell’s support, we can increase our hospital bed capacity and when the COVID-19 situation is resolved, these wards can be utilized for patients with other respiratory diseases. We are pleased to continue to work closely with Shell, the partner who shares our goal of strengthening the health and safety of Thais.”
Shell places utmost importance on the health and safety of Thai people and collaborates with various sectors to help manage the impacts of COVID-19.
Mr. Panun Prachuabmoh, Country Chairman, the Shell Company of Thailand Limited
Shell Thailand supported Ramathibodi Hospital in converting conventional patient wards into Negative Pressure Rooms for treating critical COVID-19 patients
For Media Enquiries:
Corporate Relations Advisor
H+K Strategies Thailand
M: +66 (0) 2-627-3501 #218
Corporate Communications Lead
The Shell Company of Thailand Limited
The companies in which Royal Dutch Shell plc directly and indirectly owns investments are separate legal entities. In this press release “Shell”, “Shell group” and “Royal Dutch Shell” are sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Royal Dutch Shell plc and subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ‘‘Subsidiaries’’, “Shell subsidiaries” and “Shell companies” as used in this press release refer to entities over which Royal Dutch Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as “joint ventures” and “joint operations”, respectively. Entities over which Shell has significant influence but neither control nor joint control are referred to as “associates”. The term “Shell interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.
This press release contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Royal Dutch Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Royal Dutch Shell to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition’, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. There are a number of factors that could affect the future operations of Royal Dutch Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this press release, including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell’s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; and (m) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Royal Dutch Shell’s 20-F for the year ended December 31, 2017 (available at www.shell.com/investor and www.sec.gov ). These risk factors also expressly qualify all forward looking statements contained in this press release and should be considered by the reader. Each forward-looking statement speaks only as of the date of this press release, 4th August 2021. Neither Royal Dutch Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this press release.
We may have used certain terms, such as resources, in this press release that United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. U.S. Investors are urged to consider closely the disclosure in our Form 20-F, File No 1-32575, available on the SEC website www.sec.gov.